Medulloblastoma (group 3)

Medulloblastoma - group 3 tumours are malignant tumours of the central nervous system, and one of the most common pediatric tumours. They typically arise from the vermis of the cerebellum and present in childhood and infancy. They have the worst prognosis of all medulloblastoma subgroups.  

Group 3 tumours account for approximately 27% of all medulloblastomas, and have a predilection for males, with a 2:1 male to female ratio 1

They are most frequently encountered in children (4-16 years of age) and infants but are rarely seen in adults 1-2

The majority of Group 3 medulloblastomas have classic or large cell/anaplastic histology 2. They are associated with MYC amplification 2

The radiographic features of group 3 tumours are similar to group 4 tumours (which we typically associate with medulloblastomas; midline masses arising from the vermis). Unlike group 4 tumours, group 3 tumours tend to be less well defined but have more prominent enhancement 3

For more details on radiographic features please refer to the general article on medulloblastomas.  

Surgery is the first line of therapy (as is the case in all subgroups) with the aim being histological proof, molecular subtyping and maximal tumour resection, with adjuvant therapy depending on an overall risk profile (see general article on medulloblastoma2

The incidence of CNS metastatic disease in Group 3 tumours at diagnosis is common, found in 30% of all cases, and is even more frequent in infants (47%) 1-2

Group 3 tumours have the worse prognosis compared to other subtypes of medulloblastoma, similar to group 4 tumours, but significantly worse than SHH and WNT subtypes 1-2:

  • 39% 10-year overall survival in infants
  • 50% 10-year overall survival in children 

Prognosis is also influenced by histological subtype. 

Share article

Article information

rID: 41025
Synonyms or Alternate Spellings:

Support Radiopaedia and see fewer ads

Updating… Please wait.

Alert accept

Error Unable to process the form. Check for errors and try again.

Alert accept Thank you for updating your details.